Back to search

Peptide record

TPDB07846

B11 Antibacterial Anticancer standard
15 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB07846
B11
Antibacterial Anticancer
Anti-infective peptides Cancer-related peptides
AntiBP3 Peptipedia CancerPPD 2.0
standard
No
A 15-aa standard natural multi-activity (Antibacterial and Anticancer) peptide sequence curated from AntiBP3, Peptipedia, and CancerPPD 2.0, with an available 3D structural model.
Sequence
RIRDAIAHGYIVDKV
Physicochemical Analysis
C77H128N24O21
NCEQLMFPSTW
I
1726.01
9.74
4
2
8
+1
3.97
0.047
130.00
Mammalian: 1 hour Yeast: 2 min E.coli: 2 min
1490
86.33
1
Residue Composition
number
2
A
2
R
0
N
2
D
0
C
0
E
0
Q
1
G
1
H
3
I
0
L
1
K
0
M
0
F
0
P
0
S
0
T
0
W
1
Y
2
V
Amino Acid Distribution
A: 2 R: 2 N: 0 D: 2 C: 0 E: 0 Q: 0 G: 1 H: 1 I: 3 L: 0 K: 1 M: 0 F: 0 P: 0 S: 0 T: 0 W: 0 Y: 1 V: 2
Chemical Descriptors
15
C77H128N24O21
1726.01
9.74
+1
3.97
0.047
Free
L
Linear
Free
Antimicrobial
Litopenaeus vannamei hemocyanin-derived peptide
Evidence Records 3 records
Evidence 1 Activity

Activity

Decreased cell viability by 20% at 50 µg/mL
Anticancer

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTS assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2018

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

Decreased cell viability by 23% at 50 µg/mL
Anticancer

Target

Liver Cancer
HepG-2
Liver

Assay & Model

MTS assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2018
Evidence 3 Activity

Activity

Decreased cell viability by 13% at 50 µg/mL
Anticancer

Target

Esophageal Cancer
EC-109
Esophagus

Assay & Model

MTS assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2018